Emergent BioSolutions CFO Richard Lindahl to Step Down; Frank Vargo Named Interim CFO

Emergent BioSolutions (EBS) announced CFO Richard Lindahl will step down by Dec 31, 2026, and retire by Mar 31, 2027. Frank Vargo, VP of Treasury, will serve as interim CFO starting Jan 1, 2027.

Original reporting
Published Oct 16, 2026, 11:53 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 16, 2026, 11:55 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Emergent BioSolutions CFO Richard Lindahl to Step Down; Frank Vargo Named Interim CFO — source image
Decision brief

The 30-second read

$EBSNeutralLow
01

Why it matters

The leadership change may lead to short‑term stock volatility and longer‑term adjustments to guidance.

02

Market read

Executive turnover is a material corporate event that can affect investor perception and future earnings forecasts.

03

What to watch

Potential internal restructuring or cost‑saving measures not disclosed.

Relevance 7/10Novelty 6/10Timing: immediate announcement

Background

The filing is an SEC Form 8‑K reporting a senior executive transition at Emergent BioSolutions.

Company-level read

Ticker impact

$EBSNeutralHigh confidence
Context

Emergent BioSolutions announced its CFO Richard Lindahl will step down and Frank Vargo will become interim CFO.

Expected impact

potential modest pressure as the market assesses the leadership change

Evidence & confidence

CFO changes are material corporate actions that can influence future earnings forecasts.

Market effects

May prompt analysts to review financial outlook for the biotech sector.

Limited to U.S. biotech investors.

Minimal global impact.

Counterpoint

The CFO change could be seen as a positive sign of proactive succession planning.

Key entities

  • Richard Lindahl

    Outgoing CFO of Emergent BioSolutions.

  • Frank Vargo

    Appointed interim CFO effective Jan 1, 2027.

Related articles

$EBSMedAI 8/10

Emergent BioSolutions Inc (EBS) (Q3 2026) Earnings Call Highlights: Revenue Timing Weighs

Emergent BioSolutions reported Q3 2026 revenue of $110M, down from $231M in Q3 2025 due to MCM delivery timing. Adjusted EBITDA was -$5M, with adjusted gross margin at 28%. Full-year 2026 revenue guidance was updated to $600M-$645M. The company faces competitive pricing pressure in the naloxone market and expects MCM revenues to decline. CFO Richard Lindahl is retiring, and net leverage remained stable at 2.4 times.

$EBSMedAI 8/10

Emergent BioSolutions 2026: Revenue $110M, EPS ($0.64) — 10-Q Summary

Emergent BioSolutions reported Q3 2026 revenue of $110M, a 52.4% YoY decline, and a net loss of $32.7M, compared to a profit of $51.2M a year earlier. Nine-month revenue fell 16% to $500.4M, driven by lower NARCAN sales and declines in medical countermeasure products. The company reduced its workforce by 90 employees in August to cut costs.

$EBSMed

Emergent BioSolutions (EBS) Q3 2026 Earnings Call Transcript

Emergent BioSolutions reported Q3 2026 revenue of $110M, within guidance, bringing YTD revenue to $500M. Adjusted EBITDA reached $128M (25% margin), with $122M in operating cash flow. The company highlighted progress in its transformation plan, including contract modifications and international sales. CFO Rich Lindahl announced his retirement, with Frank Vargo assuming the role in 2027. The company also discussed its role in biodefense and AI partnerships for clinical development.

$EBSMed

Emergent Biosolutions Q3 Earnings Call Highlights

Emergent Biosolutions reported Q3 cash of $176M, reduced gross debt by $179M YoY, and repurchased $75M in bonds. MCM revenue was $59M, with international sales contributing $72M. Naloxone market faced competition. 2026 revenue guidance updated to $600M-$645M. CFO to retire, interim replacement named. (EBS)